Back to Agenda
Session 5: Acceptance of Evidence in Decision Making – Using Available Evidence at Launch for Access Decisions
Speaker(s)
Using RCT Data for HTA Strategies - Best Available Evidence at Launch to Qualify Benefits of New Medicines
William Malbecq, DRSC
MSD, Belgium
Head of Biostatistics Europe
Experience from NoMA
Anja Schiel, PHD
Norwegian Medical Products Agency (NOMA), Norway
Special Advisor, Lead Methodologist/Statistician; NOMA
Regulatory Tools to drive post-licensing evidence generation
Solange Corriol-Rohou, DrMed, MD, PHD
SCR Consulting, France
Have an account?